期刊文献+

小涎腺腺样囊性癌52例临床分析 被引量:3

Clinical analysis of 52 cases of adenoid cystic carcinoma in minor salivary gland
原文传递
导出
摘要 目的分析小涎腺腺样囊性癌(adenoid cystic carcinoma,ACC)的预后及其影响因素,探讨合理治疗方法。方法回顾性分析52例ACC的临床资料,按照美国癌症联合委员会(American Joint Committee on Cancer,AJCC)临床分期标准Ⅰ期3例(6%)、Ⅱ期11例(210k)、Ⅲ期14例(27%),Ⅳ期24例(46%)。计数资料采用)(2检验或精确概率法,Kaplan—Meier法计算生存率、累积局部控制率和远处控制率,组间比较采用Log—rank对数秩检验,Cox比例风险模型进行多因素分析。结果52例均手术治疗,39例(75%)接受术后放疗。治疗后区域复发率37%,远处转移率21%。5、10年累积局部控制率分别为68%和630k;5、10年累积远处控制率为86%和68%;5、10年肿瘤相关生存率分别为70%和54%。Cox多因素分析显示:T分期、淋巴结转移和神经侵犯与小涎腺ACC的肿瘤相关生存率有关(P〈0.05)。结论小涎腺ACC治疗失败的主要原因是复发和转移。T分期、淋巴结转移和神经侵犯是其独立预后因素。根治性手术以及合理的术后放疗是治疗小涎腺ACC的主要方法。 [ Abstract] Objective To investigate the prognosis of adenoid cystic carcinoma (ACC) in minor salivary glands and its influencing factors. Methods Clinical data of 52 patients with ACC in minor salivary glands were reviewed. The distribution of stage was as follows: stage I (6%), stage ]I (21%), stagelU (27%) and stage 1V(46% ). Counting data was analyzed by ~2 test or Fisher's exact. Survival rates were calculated by Kaplan-Merier method. Statistical significance of differences in the cumulative survival curves was evaluated using the Log-rank test. Multivariate analysis was performed by Cox proportional hazard model. Results All patients underwent primary tumor radical resection, 39 patients (75%) received postoperative radiation. The regional recurrence rate was 37% and distant metastasis rate was 21%. The 5-, 10-year cumulative local control rate were 68% and 63% respectively. The 5-, 10-year cumulative distant control rate were 86% ,68% respectively. The 5-, 10-year tumor specific survival rates were 70% and 54% respectively. Multivariate analysis showed that T stage, lymph node metastasis and perineural invasion were relevant to the tumor specific survival of ACC in minor salivary glands. Conclusions Recurrence and metastasis were the main cause of treatment failure of ACC in minor salivary glands. T stage, lymph node metastasis and perineural invasion were the independent prognostic factors of ACC in minor salivary glands. Radical surgery and reasonably postoperative radiotherapy were the main treatment strategy.
出处 《中华口腔医学杂志》 CAS CSCD 北大核心 2012年第12期705-710,共6页 Chinese Journal of Stomatology
关键词 涎腺肿瘤 腺样囊性癌 预后 Salivary gland neoplasms Adenoid cystic carcinoma Prognosis
  • 相关文献

参考文献22

  • 1Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol,2010,17 (6) : 1471-1474.
  • 2Szanto PA, Luna MA, Tortoledo ME, et al. Histologic grading of adenoid cystic carcinoma of the salivary glands. Cancer, 1984,54 (6) : 1062-1069.
  • 3] Pons Vicente O, Almendros Marqu6s N, Berini Ayt6s L, et al. Minor salivary gland tumors: a clinicopathological study of 18 cases. Med Oral Patol Oral Cir Bucal,2008,13 (9) :E582-588.
  • 4Martfnez-Rodriguez N, Leco-Berrocal I, Rubio-Alonso L, et al. Epidemiology and treatment of adenoid cystic carcinoma of the minor salivary glands: a meta-analytic study. Med Oral Patol Oral Cir Bucal, 2011,16(7) :e884-889.
  • 5Agarwal JP, Jain S, Gupta T, et al. Intraoral adenoid cystic carcinoma: prognostic factors and outcome. Oral Oncol,2008,44 (10) :986-993.
  • 6Bianchi B, Copelli C, Cocchi R, et al. Adenoid cystic carcinoma of intraoral minor salivary glands. Oral Oncol, 2008,44 ( 11 ) : 1026-1031.
  • 7张芹,杨蕾,杨安奎,郭朱明.鼻腔鼻窦腺样囊性癌88例临床分析[J].中华耳鼻咽喉头颈外科杂志,2009,44(4):311-314. 被引量:12
  • 8Ko YH, Lee MA, Hong YS, et al. Prognostic factors affecting the clinical outcome of adenoid cystic carcinoma of the head and neck. Jpn J Clin 0ncol,2007,37( 11 ) :805-811.
  • 9郑刚,郭传瑸,俞光岩,黄敏娴,彭歆,黄俊.腺样囊性癌患者生存预测模型的建立[J].中华口腔医学杂志,2006,41(6):350-353. 被引量:13
  • 10da Cruz Perez DE, de Abreu Alves F, Nobuko Nishimoto I, et al. Prognostic factors in head and neck adenoid cystic carcinoma. Oral 0ncol,2006,42(2) :139-146.

二级参考文献54

  • 1刘文胜,唐平章,祁永发,高黎,李正江.腭部腺样囊性癌的诊治及预后因素的探讨[J].中华肿瘤杂志,2004,26(8):485-489. 被引量:27
  • 2吕春堂,周树夏,周中华,孙沫逸.涎腺腺样囊性癌热点问题研究[J].第二军医大学学报,2005,26(6):589-592. 被引量:4
  • 3马大权 俞光岩.腺样囊性癌:诊断和治疗探讨[J].中华口腔医学杂志,1987,22:319-322.
  • 4Matsuba HM, Spector GJ, Thawley SE, et al. Adenoid cystic salivary gland carcinoma: a histopathologic review of treatment failure patterns. Cancer, 1986,57:519-524.
  • 5Stern SJ, Hanna E. Cancer of nasal cavity and paranasal sinuses//Meyer EN, Suen JY. Cancer of the Head and Neck. 3rd ed. Philadelphia, PA : Saunders, 1996 : 205-233.
  • 6Snehal GP, Jatin PS. TNM staging of cancers of the head and neck: striving for uniformity among diversity. Cancer J Clin, 2005, 55:242-258.
  • 7李艳素.靶区放射治疗剂量//殷蔚伯.肿瘤放射治疗学.4版.中国协和医科大学出版社,2008:427-438.
  • 8Rhee CS, Won TB, Lee CH, et al. Adenoid cystic carcinoma of the sinonasal tract : treatment results. Laryngoscope, 2006,116 : 982-986.
  • 9Triantafillidou K, Dimitrakopoulos J, Iordanidis F, et al. Management of adenoid cystic carcinoma of minor salivary glands. J Oral Maxillofac Surg, 2006, 64 : 1114-1120.
  • 10Garden AS, Weber RS, Morrison WH, et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation. Int J Radiat Oncol Biol Phys, 1995,32:619-626.

共引文献37

同被引文献15

  • 1Alessi D R, Smythe C, Keyse S M. The human CL100 gene encodes a Tyr/Thr-protein phosphatase which potently and specifically inactivates MAP kinase and suppresses its activation by oncogenic ras in Xenopus oocyte extracts[J]. Oncogene, 1993, 8 (7): 2015-2020.
  • 2Ling Z Q, Guo W, Lu X X, et al, A Golgi-specific protein PAQR3 is closely associated with the progression, metastasis and prognosis of human gastric cancers[J]. Ann Oncol, 2014, 25(7): 1363- 1372.
  • 3Bermudez O, Pages G, Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer[J]. Am J Physiol Cell Physiol, 2010, 299(2): C189-202.
  • 4Liu C, Shi Y, Du Y, et al. Dual-specificity phosphatase DUSP1 protects overactivation of hypoxia-inducible factor 1 through inactivating ERK MAPK[J]. Exp Cell Res, 2005, 309(2): 410-418.
  • 5Owens D M, Keyse S M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases[J]. Oncogene, 2007, 26(22): 3203-3213.
  • 6Liu Y X, Wang J, Guo J, et al. DUSP1 is controlled by p53 during the cellular response to oxidative stress[J]. Mol Cancer Res, 2008, 6(4): 624-633.
  • 7Wang J, Yin D P, Liu Y X, et al. Dual specificity phosphatase 1/CL100 is a direct transcriptional target of E2F-1 in the apoptotic response to oxidative stress[J]. Cancer Res, 2007, 67(14): 6737- 6744.
  • 8Laderoute K R, Mendonca H L, Calaoagan J M, et al. Mitogenactivated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducibte stress-activated protein kinase/c-Jun N-terminal protein kinase activity[J]. J Biol Chem, 1999, 274(18): 12890-12897.
  • 9Moncho-Amor V, Ibanez de Cáceres I, Bandres E, et al. DUSP1/ MKP1 promotes angiogenesis, invasion and metastasis in non- small-cell tung cancer[J]. Oncogene, 2011,30(6): 668-678.
  • 10Liu F, Gore A J, Wilson J L, et al. DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine [J]. PLoS One, 2014, 9(1): e84982.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部